Featured

Biomarkers for Graft-Versus-Host Disease: Biomarkers and Alternatives to Corticosteroid Treatment



Published
In this third of a four-part series, Sophie Paczesny, M.D., Ph.D., discusses how a predictive biomarker for acute graft-versus-host disease (GVHD) might help identify patients who could be treated with an alternative to corticosteroids. Results of a phase 2 trial published in the journal Blood comparing sirolimus to prednisone showed positive results for sirolimus. Paczesny is a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on GVHD and its possible biomarkers. She was the corresponding author of a review article about GVHD biomarkers published in July in the journal Transplantation and Cellular Therapy.
Category
Health
Be the first to comment